Vav1: A Dr. Jekyll and Mr. Hyde protein – good for the hematopoietic system, bad for cancer

Por Katzav, Shulamit
Publicado no Oncotarget (2015)

Human Vav1 Expression in Hematopoietic and Cancer Cell Lines Is Regulated by c-Myb and by CpG Methylation

Por Ilan, Lena, Katzav, Shulamit
Publicado em 2012

Mutations of c-Cbl in myeloid malignancies

Por Katzav, Shulamit, Schmitz, M. Lienhard
Publicado no Oncotarget (2015)

Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes

Por Shalom, Batel, Farago, Marganit, Pikarsky, Eli, Katzav, Shulamit
Publicado no Oncogenesis (2018)

Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice

Por Salaymeh, Yaser, Farago, Marganit, Sebban, Shulamit, Shalom, Batel, Pikarsky, Eli, Katzav, Shulamit
Publicado no Life Sci Alliance (2020)

Signalling pathways induced by protease-activated receptors and integrins in T cells

Por Bar-Shavit, Rachel, Maoz, Miriam, Yongjun, Yin, Groysman, Maya, Dekel, Idit, Katzav, Shulamit
Publicado em 2002

Tyrosine Residues at the Carboxyl Terminus of Vav1 Play an Important Role in Regulation of Its Biological Activity

Por Lazer, Galit, Pe'er, Liron, Farago, Marganit, Machida, Kazuya, Mayer, Bruce J., Katzav, Shulamit
Publicado em 2010

Vav1 Fine Tunes p53 Control of Apoptosis versus Proliferation in Breast Cancer

Por Sebban, Shulamit, Farago, Marganit, Gashai, Dan, Ilan, Lena, Pikarsky, Eli, Ben-Porath, Ittai, Katzav, Shulamit
Publicado em 2013

Vav1 promotes lung cancer growth by instigating tumor-microenvironment cross-talk via growth factor secretion

Por Sebban, Shulamit, Farago, Marganit, Rabinovich, Shiran, Lazer, Galit, Idelchuck, Yulia, Ilan, Lena, Pikarsky, Eli, Katzav, Shulamit
Publicado no Oncotarget (2014)

Mutation of Vav1 adaptor region reveals a new oncogenic activation

Por Razanadrakoto, Lyra, Cormier, Françoise, Laurienté, Vanessa, Dondi, Elisabetta, Gardano, Laura, Katzav, Shulamit, Guittat, Lionel, Varin-Blank, Nadine
Publicado no Oncotarget (2014)